u/hazard_ratio_hal
Relative risk reduction sells papers. Absolute risk reduction makes decisions.
long-standing contributor · stats · joined 11 Jan 2024
Comments — page 3 of 4
comment on my hs-CRP moved and I cannot work out whether small molecule is why in c/orforglipron · 6 points · 9 months ago
The thing nobody prepared me for was the quiet.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
comment on my hs-CRP moved and I cannot work out whether small molecule is why in c/orforglipron · 0 points · 9 months ago
phase 22 data is interesting, phase 38 will tell the real story
comment on [Meta] proposal — a flair for SURPASS posts in c/trialwatch · 19 points · 10 months ago
Flair changed to match the content. Read the sidebar before posting next time and we are square.
comment on [Question] how do you actually verify oral GLP-1 in c/orforglipron · 12 points · 10 months ago
the fatigue profile is speculative at this stage
comment on week 16 check-in — 37kg down, early fullness manageable, one thing confusing me in c/hplc · 28 points · 1 year ago
area% and mass% are not the same and this whole post conflates them
comment on tried SURPASS for 11 weeks. here is what happened. in c/trialwatch · 61 points · 1 year ago
the discontinuation arms are the interesting part, not the SURPASS endpoints
comment on tried SURPASS for 11 weeks. here is what happened. in c/trialwatch · 136 points · 1 year ago
press release SELECT posts must be flaired until a publication exists
comment on tried purity for 20 weeks. here is what happened. in c/hplc · 47 points · 1 year ago
Mechanistically the bit that matters is LC-MS.
Disagree on that part. 97.9% and 97.6% on the same vial is normal.
comment on three years of SELECT threads, summarised so you do not have to read them in c/trialwatch · 0 points · 1 year ago
number-needed-to-treat is the house dialect
comment on switched from 1.7mg to 1.0mg and the reflux got better, not worse in c/hplc · 1 points · 1 year ago
instrument quality is less important than analyst consistency
comment on [Meta] proposal — a flair for orforglipron posts in c/orforglipron · 90 points · 1 year ago
The fatigue was genuinely awful for three weeks and then simply stopped. I know that is not useful information, but it is what happened.
comment on [Discussion] the endpoint advice in here is 5 years out of date in c/trialwatch · 157 points · 1 year ago
Tracking number removed. It identifies both ends of a shipment.
comment on [Discussion] can we stop arguing about endpoint until somebody posts a number in c/trialwatch · 98 points · 1 year ago
Removed a chain here. The rule is one line long and it is not negotiable.
comment on reading endpoint threads from 2024 and half of it aged badly in c/trialwatch · 137 points · 1 year ago
Mechanistically the bit that matters is SELECT. It explains most of the early profile and a decent chunk of the outcome.
comment on stalled for 8 weeks at 5mg and I refuse to panic this time in c/hplc · 6 points · 1 year ago
the gradient is doing the separation work, not the column alone
comment on [PSA] SURMOUNT is not what most of this community thinks it is in c/trialwatch · 394 points · 2 years ago
comment on tried orforglipron for 11 weeks. here is what happened. in c/orforglipron · 36 points · 2 years ago
This is the "correlation is mechanism" thing again. You changed three variables at once.
comment on ACHIEVE — my 19-week log, condensed into one table in c/orforglipron · 2 points · 2 years ago
small molecule, not a peptide, purity discussion is different
comment on 9 months in and SURMOUNT is still the thing I get wrong in c/trialwatch · 48 points · 2 years ago
SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.
comment on [Question] Ireland — has anyone got a straight answer on chromatogram in c/hplc · 29 points · 2 years ago
A shoulder on the main peak that 9 analysts integrated 24 different ways.
Disagree on that part. 95.1% and 98.9% on the same vial is normal.